Crossmark

Caution in extending SGLT2 inhibitor trials to children with CAKUT: a call for phenotype-specific safety considerations

Crossref DOI link: https://doi.org/10.1007/s00467-026-07172-2

Published Online: 2026-01-22

Published Print: 2026-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Filler, Guido https://orcid.org/0000-0003-1891-6765
McIntyre, Christopher William https://orcid.org/0000-0002-3877-3135
License Information

Text and Data Mining valid from 2026-01-22

Version of Record valid from 2026-01-22
More Information

Article History

Received: 4 January 2026

Revised: 10 January 2026

Accepted: 14 January 2026

First Online: 22 January 2026

Declarations

:

: The authors declare no competing interests.